Toxic Epidermal Necrolysis clinical trials

Explore recruiting toxic epidermal necrolysis clinical trials.

Recruiting toxic epidermal necrolysis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Toxic Epidermal Necrolysis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

New therapeutic approach to Toxic Epidermal Necrolysis (TEN) using anti-CD38+ antibodies in the active phase of the disease – Phase I/II study to assess the tolerance and efficacy of DARATUMUMAB - NET-CD38 Study

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Empirical Meropenem versus Piperacillin/Tazobactam for Adult Patients with Sepsis (EMPRESS) trial

Denmark, Sweden

Therapeutic use (Phase IV) EU CTIS Study details

Toxic Epidermal Necrolysis trials by city

Toxic Epidermal Necrolysis in Toronto Toxic Epidermal Necrolysis in Vancouver Toxic Epidermal Necrolysis in Montreal Toxic Epidermal Necrolysis in Calgary Toxic Epidermal Necrolysis in Edmonton Toxic Epidermal Necrolysis in Ottawa Toxic Epidermal Necrolysis in Winnipeg Toxic Epidermal Necrolysis in Quebec City Toxic Epidermal Necrolysis in Hamilton Toxic Epidermal Necrolysis in Kitchener Toxic Epidermal Necrolysis in London Toxic Epidermal Necrolysis in Halifax Toxic Epidermal Necrolysis in New York Toxic Epidermal Necrolysis in Los Angeles Toxic Epidermal Necrolysis in Chicago Toxic Epidermal Necrolysis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease